fogpharma.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $506.63MM
FogPharma is a clinical-stage biotechnology research company striving to develop HeliconTM peptides, an innovative approach aimed at overcoming current medication limitations and creating drug solutions for all human disease drivers. The Helicons are intended to act similarly to antibodies and be allocated across tissue as they interact with small molecules within the cells, whereas most modern tailored medications have difficulty reaching these target areas. FogPharma was founded in 2016 and is headquartered in Cambridge, Massachusetts.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like FogPharma.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.